Table 4.
Change in intensity of symptoms from baseline to each visit for patients from the effectiveness population who underwent radiotherapy or a TURP.
| At baseline (n = 53) | |||
|---|---|---|---|
| Mild symptoms | Moderate symptoms | Severe symptoms | |
| At week 24 (n = 46) | |||
| (P = 0.017* versus baseline) | |||
| No symptoms | 1 (2.2%) | 0 (0%) | 0 (0%) |
| Mild symptoms | 14 (30.4%) | 9 (19.6%) | 1 (2.2%) |
| Moderate symptoms | 1 (2.2%) | 16 (34.8%) | 0 (0%) |
| Severe symptoms | 1 (2.2%) | 1 (2.2%) | 2 (4.3%) |
| At week 48 (n = 49) | |||
| (P = 0.027* versus baseline) | |||
| No symptoms | 2 (4.1%) | 0 (0%) | 0 (0%) |
| Mild symptoms | 15 (30.6%) | 12 (24.5%) | 0 (0%) |
| Moderate symptoms | 3 (6.1%) | 13 (26.5%) | 2 (4.1%) |
| Severe symptoms | 0 (0%) | 1 (2.0%) | 1 (2.0%) |
| At last available visit (n = 53) | |||
| (P = 0.005* versus baseline) | |||
| No symptoms | 2 (3.8%) | 0 (0%) | 0 (0%) |
| Mild symptoms | 15 (28.3%) | 14 (26.4%) | 1 (1.9%) |
| Moderate symptoms | 3 (5.7%) | 14 (26.4%) | 2 (3.8%) |
| Severe symptoms | 0 (0%) | 1 (1.9%) | 1 (1.9%) |
*Bhapkar's test for homogeneity. Note: percentages are based on the number of patients with available responses. To operate Bhapkar's test, a frequency equal to 0 was replaced by 0.001.